Daily Bulletin

The Times Real Estate

.

  • Written by PR Newswire Asia - Daily Bulletin Au RSS

World's First Genetically Recombinant Collagenase Therapeutics (CNT201) Begins Clinical Trials in Australia

SEOUL, South Korea, July 30, 2024 /PRNewswire/ -- Connext has announced the successful first administration of CNT201, its therapeutic treatment for Dupuytren's contracture, in patients.

Dupuytren's contracture is a debilitating condition characterized by the fibrosis of the fascia between the skin and tendons of the palm due to collagen buildup, causing fingers to become permanently bent and significantly impairing patients' quality of life. Currently, there is no fundamental cure for this condition. Treatments primarily involve surgical interventions like fasciectomy to alleviate symptoms, although non-surgical methods, such as localized injections of collagenase, have shown high patient satisfaction.

It has received IND approval for Phase 1/2 clinical trials from the U.S. FDA and recently completed the Clinical Trial Notification (CTN) process in Australia. The ongoing clinical trial in Australia represents the Phase 1 part of the Phase 1/2 trial, conducted across three hospitals. The trial involves single administrations of four escalating dose levels in patients with Dupuytren's contracture, followed by a four-week evaluation period to assess safety, tolerability, efficacy, pharmacokinetics, and immunogenicity. Connext plans to secure proof-of-concept (PoC) data by mid-next year and determine the optimal dose for Phase 2, with the aim to commence the Phase 2 trial in the latter half of the year.

Connext CEO Woojong Lee remarked, "This first administration marks a significant milestone, offering new hope to patients suffering from Dupuytren's contracture. We are dedicated to developing a safer and more effective treatment to improve their quality of life."

Connext successfully raised a Series B investment at the end of last year and was selected for the Scale-Up TIPS program, enabling the initiation of global clinical trials for Dupuytren's contracture. The company is simultaneously advancing the development of additional indications, including Peyronie's disease and cellulite.

Media Contact:Sangho Lee(Communication)+82-10-8829-4694Sangho.lee@connext.co.kr

Authors: PR Newswire Asia - Daily Bulletin Au RSS

Read more https://www.prnasia.com/story/archive/4471232_AE71232_0

Business News

How to Estimate the Right Skip Bin Size for Your Renovation Project

One of the most challenging aspects of planning a renovation project is estimating the amount of waste you'll generate. Choosing a skip bin that's too small means paying for additional bins or picku...

Daily Bulletin - avatar Daily Bulletin

Cool Room Hire: The Ultimate Solution for Temperature-Sensitive Storage

Businesses in the food, pharmaceutical, and event industries often require reliable refrigeration to keep products fresh and safe. Cool room hire provides a flexible and cost-effective solution for ...

Daily Bulletin - avatar Daily Bulletin

Thryv Australia named global winner of the 2025 Microsoft Advertising Partner Awards

Melbourne – 11 March 2025:   Thryv® (NASDAQ: THRY), provider of the leading small business marketing and sales software platform, has been named the global winner of the Microsoft Advertising Part...

Daily Bulletin - avatar Daily Bulletin

LayBy Deals